Pharming Group (PHGUF) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharming Group has received U.K. marketing authorization for Joenja® (leniolisib), a novel treatment for activated phosphoinositide 3-kinase delta syndrome in patients aged 12 and above. This marks the first U.K. approval for a medication specifically targeting APDS, a rare immunodeficiency disease, and represents the third country approval for Pharming’s treatment. The company’s CEO highlights this as a significant step towards their goal of being a leading global rare disease company.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.